- Home
- GBX vs APGE Comparison
GBX vs APGE Comparison
Compare GBX & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBX
- APGE
- Stock Information
- Founded
- GBX 1974
- APGE 2022
- Country
- GBX United States
- APGE United States
- Employees
- GBX N/A
- APGE N/A
- Industry
- GBX Railroads
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GBX Industrials
- APGE Health Care
- Exchange
- GBX Nasdaq
- APGE Nasdaq
- Market Cap
- GBX 2.1B
- APGE 2.3B
- IPO Year
- GBX N/A
- APGE 2023
- Fundamental
- Price
- GBX $54.55
- APGE $34.55
- Analyst Decision
- GBX Hold
- APGE Strong Buy
- Analyst Count
- GBX 3
- APGE 5
- Target Price
- GBX $64.00
- APGE $83.50
- AVG Volume (30 Days)
- GBX 401.6K
- APGE 499.8K
- Earning Date
- GBX 04-04-2025
- APGE 03-04-2025
- Dividend Yield
- GBX 2.19%
- APGE N/A
- EPS Growth
- GBX 73.07
- APGE N/A
- EPS
- GBX 5.73
- APGE N/A
- Revenue
- GBX $3,611,800,000.00
- APGE N/A
- Revenue This Year
- GBX $2.49
- APGE N/A
- Revenue Next Year
- GBX $2.20
- APGE N/A
- P/E Ratio
- GBX $9.58
- APGE N/A
- Revenue Growth
- GBX N/A
- APGE N/A
- 52 Week Low
- GBX $41.40
- APGE $32.46
- 52 Week High
- GBX $71.06
- APGE $72.29
- Technical
- Relative Strength Index (RSI)
- GBX 23.03
- APGE 35.39
- Support Level
- GBX $53.33
- APGE $32.46
- Resistance Level
- GBX $65.02
- APGE $37.42
- Average True Range (ATR)
- GBX 1.85
- APGE 2.17
- MACD
- GBX -1.16
- APGE -0.30
- Stochastic Oscillator
- GBX 9.41
- APGE 20.84
About GBX Greenbrier Companies Inc. (The)
Greenbrier Companies Inc designs, manufactures, and markets railroad freight car equipment in North America and Europe, marine barges in North America and provides wheel services, railcar refurbishment, and parts, leasing and other services to the railroad. Its segments include Manufacturing, Maintenance Services and Leasing & Management Services. The company generates a majority of its revenue from the manufacturing segment. Geographically, it derives a majority of revenue from the United States.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.